fter months of pursuit, Takeda Pharmaceuticals (TKPYY) finally won over Shire (SHPG) with a $62 billion offer, a move that will create the world’s eighth-largest drug maker with combined sales worth $30 billion. And for Takeda chief executive Christophe Weber, the deal will cap his quest to expand the Japanese drug maker into more profitable markets, notably the U.S.

Once completed — the target date is the first half of 2019 — the combined company will become a leader in therapies for a variety of maladies. But Takeda is borrowing cash to pay for the deal, worrying shareholders about its debt load, especially after borrowing money to buy Ariad Pharmaceuticals last year for $5 billion.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • What a waste of money! There will be no respectable return on investment in five even in ten years.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy